Jefferies Group LLC reaffirmed their buy rating on shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in a research report sent to investors on Sunday, November 5th. They currently have a $16.00 price target on the specialty pharmaceutical company’s stock.
A number of other research analysts also recently commented on AMAG. BidaskClub downgraded AMAG Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, August 10th. Cowen Inc restated a hold rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. Cantor Fitzgerald restated a hold rating and issued a $21.00 target price on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. Janney Montgomery Scott reiterated a hold rating on shares of AMAG Pharmaceuticals in a research note on Tuesday, October 17th. Finally, Morgan Stanley decreased their price target on AMAG Pharmaceuticals from $26.00 to $22.00 and set an overweight rating for the company in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $24.00.
AMAG Pharmaceuticals (NASDAQ:AMAG) traded down $0.45 during trading hours on Friday, reaching $14.20. The company had a trading volume of 252,635 shares, compared to its average volume of 1,109,468. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $36.83. The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.